Treatment of Anemia in Cancer Patients on Chemotherapy: Erythropoietin is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. Erythropoietin is indicated to decrease the need for transfusions in patients who will be receiving concomitant chemotherapy for a minimum of 2 months.
Treatment of Anemia in Zidovudine-treated HIV-infected Patients: Erythropoietin is indicated for the treatment of anemia related to therapy with zidovudine in HIV-infected patients. Erythropoietin is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or hemoglobin determinations) and to decrease the need for transfusion in these patients.
Reduction of Allogeneic Blood Transfusions in Surgery Patients: Erythropoietin is indicated for the treatment of anemic patients (hemoglobin >10 to ≤13 g/dL) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. Erythropoietin is indicated for patients at high risk of perioperative transfusions with significant, anticipated blood loss. Erythropoietin is not indicated for anemic patients who are willing to donate autologous blood. The safety of the perioperative use of erythropoietin has been studied only in patients who are receiving anticoagulant prophylaxis.